Resilient Biotics is developing non-antibiotic, microbiome-based therapeutics to combat complex respiratory infections with applications in human and animal health. The company utilizes a proprietary discovery platform that incorporates high resolution genomic analyses, in-house machine learning algorithms, and targeted in vitro assays to identify naturally occurring microbiome-derived strains that have immune activation and pathogen inhibition properties in respiratory tissues. Resilient Biotics has a broad pipeline of actives addressing both viral and bacterial infectious diseases including positive in vivo efficacy data across multiple species.